GLP-1 Daily: Ozempic & Wegovy News

An advocacy group is pushing Ohio to rewrite the rule that keeps its Medicaid program from covering GLP-1s for adult obesity, while a large, preliminary health-records study for the American Heart Association links GLP-1s to better prediabetes outcomes than metformin. Australia's drug regulator has also approved the Wegovy pill.

In this episode

• Group seeks Ohio Medicaid coverage for GLP-1 weight-loss drugs — Daytondailynews

“The Ohio Department of Medicaid is prohibited from covering GLP-1 medications specifically for the condition of obesity in adults due to a restriction in the Ohio administrative code, but a national organization is advocating for state officials to change this.”

• GLP-1 meds linked to lower diabetes, heart risks than standard diabetes prevention med | American Heart Association — American Heart Association

“GLP-1 (glucagon-like peptide-1 receptor agonists) medications, currently popular for weight-loss, may help prevent Type 2 diabetes and lower the risk of heart attack and stroke more than the standard diabetes prevention medication metformin among people with prediabetes,…”

• Watchdog’s huge call on weight-loss drug pill - Yahoo News Australia — Emma Kirk

“A Department of Health spokesman said the TGA approved the registration of a Wegovy oral tablet in 1.5mg, 4mg, 9mg and 25mg strengths.”

Daily TopFive for GLP-1 Daily: Ozempic & Wegovy News. Links above go to the original articles. Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com.

As employers drop weight-loss GLP-1 coverage for 2027, Novo Nordisk's deal with Andel and GoodRx's new Employer Direct let companies chip in on cash prices outside insurance. Plus: South Korea's prescriptions and intercepted illegal imports surge, and Sun Pharma gets Indian approval for a generic semaglutide diabetes pill.

In this episode

• As Employers Pull Back on GLP-1s, Andel and Novo Offer a Workaround — Ajmc

“The deal covers both injectable semaglutide, including the higher-dose semaglutide HD, and the once-daily semaglutide pill. Each employer chooses how much to contribute toward treatment, which lowers what employees pay out of pocket while the employer keeps control over its…”

• Koreans aren't rushing to embrace homegrown weight-loss drug — yet | Aju Press — Aju Press

“Lawmakers say price differences have encouraged purchases abroad. The Korea Customs Service intercepted illegally imported obesity drugs 5,030 times in the first eight months of this year, 4.2 times the total for 2025.”

• Sun Pharma Secures Approval for Generic Semaglutide Pill in India, ETPharma — Abhijeet Singh

“Indian Pharma major, Sun Pharmaceutical Industries has secured regulatory nod to manufacturer and market its generic semaglutide pill in India. The once-daily drug, therapeutically equivalent to Novo’s Rybelsus, is approved for the treatment for type-2 diabetes and covers three…”

Daily TopFive for GLP-1 Daily: Ozempic & Wegovy News. Links above go to the original articles. Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com.

A preliminary Truveta analysis finds GLP-1 prescribing to adults 65 and older stayed about 21 percent above June levels three months after the Medicare GLP-1 Bridge launched, while Hanmi's Eppe began prescriptions in South Korea at a starter price undercutting Mounjaro and Wegovy. A Novo-funded pooled analysis of SELECT, FLOW and SOUL links semaglutide to fewer major kidney outcomes.

In this episode

• GLP-1 prescriptions still up three months into Medicare Bridge pilot — Truveta Research

“GLP-1 prescribing among adults aged 65 years and older increased from June to July following implementation of the Medicare GLP-1 Bridge and remained relatively stable thereafter, with prescribing 20.6% higher three months after implementation than in June. The initial increase…”

• Korea’s First Homegrown Obesity Drug Begins Prescriptions, Challenging Mounjaro on Price - Businesskorea — Choi Mun-hee

“Eppe’s main competitive advantage is its price. According to pharmaceutical industry sources, the supply price for the first four weeks of treatment is approximately 129,800 won ($97.20), about half the roughly 270,000 won for Eli Lilly’s Mounjaro and around 40% less than the…”

• Semaglutide Slows Kidney Function Decline in High-Risk Patients — Lisa Kuhns, PhD

“Semaglutide reduces clinically important kidney outcomes and slows kidney function decline, with benefits generally consistent across baseline kidney function, diabetes status, adiposity, and type of administration, according to results of a study published in The Lancet…”

Daily TopFive for GLP-1 Daily: Ozempic & Wegovy News. Links above go to the original articles. Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com.

Eli Lilly reports company topline phase 3 results showing its experimental retatrutide beat Ozempic 2 mg on blood sugar and weight in type 2 diabetes, with more side-effect dropouts. HHS paused enforcement against pharmacies compounding six unapproved peptides, and a JAMA study from Nebraska finds compounded GLP-1s widely mixed with B12 and other additives.

In this episode

• Lilly's 'triple-G' drug tops Novo's Ozempic in diabetes trial — Jonathan Gardner

“Those benefits appear to come with a trade-off. In the study, only 3% of Ozempic recipients stopped treatment because of side effects compared with 8% of the people on the highest retatrutide dose and 5% of those in the 9 mg group.”

• RFK Jr. takes shortcut to make some unapproved peptides available for use — NBC News

“In a notice filed Wednesday, the agency said it would exercise “enforcement discretion,” meaning it will not take legal action against compounding pharmacies that make the six unapproved peptides. In practice, that means these pharmacies can start offering them now, even though…”

• Compounded GLP-1s Coformulated With B12, Other Additives — Marilynn Larkin

“Compounded GLP-1s contain ingredient combinations not found in FDA-approved products, introducing uncertainty about composition, purity, and potency, according to a new study. The authors argue this warrants mandatory testing and adverse-event reporting for mass-compounded…”

Daily TopFive for GLP-1 Daily: Ozempic & Wegovy News. Links above go to the original articles. Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com.

A WTW survey reported by CNBC finds employer coverage of weight-loss GLP-1s falling for the first time in three years, as Walgreens rolls out prior-authorization and Medicare Bridge help. Vanda says its pill tradipitant cut semaglutide-induced vomiting in a company-reported phase 3 trial.

In this episode

• GLP-1 coverage is being dropped by employers: 2027 weight-loss options — CNBC

“A WTW annual health benefits survey fielded over the summer and being released in full on Wednesday found that 53% of employers with more than 100 employees cover GLP-1s for weight loss, down from 57% in 2025. That's the first decline in three years. What's more, 16% of…”

• Walgreens Adds Pharmacist Outreach, Coverage Help for GLP ... — Pharmacy Times

“Walgreens is expanding its weight management services to help eligible patients navigate coverage for glucagon-like peptide-1 (GLP-1) receptor agonists prescribed for weight loss. The additions include virtual care support for commercial insurance checks, prior authorization…”

• Tradipitant Cuts Semaglutide-Induced Vomiting in Phase 3 Trial — Hcplive

“All participants received a single 1 mg dose of semaglutide without the gradual titration used in clinical practice. Vanda described this as a highly emetogenic test condition.”

Daily TopFive for GLP-1 Daily: Ozempic & Wegovy News. Links above go to the original articles. Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com.

A federal judge on Monday refused Novo Nordisk's bid to halt Eli Lilly's comparative weight-loss ads while the suit continues, and South Korea's health minister put obesity drugs up for a managed-insurance review at a hearing that exposed ignored prescribing alerts. Plus, generic semaglutide maker Dr. Reddy's aims to restart supply in November if validation succeeds.

In this episode

• US judge refuses to block Eli Lilly weight-loss drug ads, rules against Novo Nordisk — StreetInsider

“Quraishi called Novo Nordisk's claim of irreparable harm "inadequate to warrant the extraordinary relief it seeks." The judge ruled after a two-day hearing in late August.”

• Korea Weighs Putting Obesity Drugs Under Health Insurance Controls - Seoul Economic Daily — Park Hong-yong

“The managed benefit scheme brings non-reimbursed items at risk of overtreatment into the national health insurance system so that prices and treatment standards can be managed. It sets the patient co-payment rate at 95%, aiming to curb indiscriminate use of medical services…”

• Dr Reddy's Plans 6-7 Million Semaglutide Pens by March — Drew Thornley

“Dr Reddy's Laboratories expects to relaunch generic semaglutide in Canada in November and has kept its guidance of 6 million to 7 million pens across 10 approved markets between November and March, with Canada taking most of the volume, Narasimham told Moneycontrol in an…”

Daily TopFive for GLP-1 Daily: Ozempic & Wegovy News. Links above go to the original articles. Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com.

South African regulators admit they're on the back foot against bulk-compounded and black-market weight-loss jabs, and Belgium refuses to reimburse Mounjaro for obesity. A JAMA Network Open study finds about half of early Wegovy pill starters were new to GLP-1s.

In this episode

• SA regulators struggle to control illegal weight-loss jabs — Daily Maverick

“But some pharmacies produce large quantities without that evidence, Sahpra chief executive Boitumelo Semete-Makokotlela told Bhekisisa. This means “you’re not compounding, you are manufacturing”, which requires a good manufacturing practice licence that compounding pharmacies do…”

• Belgium Rejects Reimbursement for Mounjaro in Obesity Treatment | NAVLIN DAILY — NAVLIN DAILY

“Belgium’s Health Minister Frank Vandenbroucke decided against reimbursing Eli Lilly’s Mounjaro (tirzepatide) for obesity treatment, citing budget and medical concerns, stressing that obesity needs more than just medication—it requires support from dietitians, psychologists, and…”

• Oral Semaglutide Uptake Near Injectable Levels Within 3 ... — AJMC

“Overall, 53.0% of oral semaglutide initiators had no GLP-1 RA use in the prior 12 months. The most common prior exposures were injectable semaglutide (28.9% of all oral semaglutide initiators) and injectable tirzepatide (27.5%).”

Daily TopFive for GLP-1 Daily: Ozempic & Wegovy News. Links above go to the original articles. Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com.

Mass General Brigham confirms affected employee plans will stop covering GLP-1s for weight loss on January 1, 2027, and British MPs say the NHS plan for Mounjaro reaches only about 6% of eligible people. CBS News lab-tested vials sold as retatrutide and found one held no peptide at all, plus bacteria.

In this episode

• EXCLUSIVE: Mass General Helped Give the World GLP-1. Now Its Own Benefits Are Pulling Back Obesity Drug Coverage | On The Pen — On The Pen GLP-1 News

“Beginning January 1, 2027, GLP-1 medications prescribed for weight loss will no longer be covered through the pharmacy benefit of affected Mass General Brigham employee medical plans. Coverage for GLP-1 medications prescribed for diabetes will continue, subject to plan coverage…”

• Give more people weight loss jabs on the NHS, say MPs - BBC News — BBC News

“The Health Committee said the current plan for 220,000 people to have this jab for free on prescription in 2028 was a "woefully small number" and "unambitious".”

• We bought and tested what was sold as an experimental weight loss drug. The lab results were "pretty terrifying." - CBS News — Adam Yamaguchi Correspondent

“Instead, Galpin found a compound called phenylacetic acid, which he described as a filler. It's commonly found in fragrances and lip balms.”

Daily TopFive for GLP-1 Daily: Ozempic & Wegovy News. Links above go to the original articles. Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com.

A Los Angeles judge sent a patient's lawsuit, which says Anthem cut off Zepbound because it worked, to private arbitration. Also today: telehealth companies offering GLP-1s off-label for addiction, and what the SOUL trial does and doesn't show about oral semaglutide and the kidneys.

In this episode

• Obese Woman Ordered to Arbitrate Claims vs. Anthem Over Zepbound Denial - MyNewsLA.com — Mynewsla

““Despite this knowledge, Anthem intentionally and wrongfully refused Zepbound for Alicia simply because the drug began to work for her and lowered her weight to where she was no longer morbidly obese,” according to the suit.”

• STAT+: Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction — STAT

“But some telehealth platforms that specialize in treating addiction aren’t waiting. In the last year, a few companies have begun to market off-label prescriptions of GLP-1s, both branded and compounded, to treat alcohol use disorder and other addictions.”

• Oral Semaglutide Kidney Outcomes in SOUL | PeptideMethods — PeptideMethods

“The kidney signal in SOUL was a change in an eGFR measure, not evidence that oral semaglutide prevented kidney failure or reduced the need for dialysis.”

Daily TopFive for GLP-1 Daily: Ozempic & Wegovy News. Links above go to the original articles. Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com.

An FDA inspection report details 14 problems at Houston RX, the pharmacy behind a nationwide recall of compounded tirzepatide vials, while Belgium's medicines agency warns against off-label GLP-1 use and black-market retatrutide. Plus, Novo's company-reported CagriSema data in women ahead of an expected FDA decision.

In this episode

• Houston Pharmacy Behind Recalled Compounded Tirzepatide Vials Drew 14 FDA Inspection Observations, Including Exposed Skin and Research-Grade Ingredients — Medical Daily

“Inspectors also wrote that on August 3 the pharmacy recovered microbial growth in the ISO 5 hood after filling a lot of tirzepatide-niacinamide. No investigation followed because the firm's action level was not appropriate, according to the FDA, and that lot was released and…”

• GLP-1 analogues and GIP/GLP-1 dual analogues: risks associated with misuse and off-label use for weight loss | FAMHP — FAMHP

“In practice: for weight loss in people who are neither obese nor demonstrably overweight – and where this is not associated with health problems – the risks associated with treatment may outweigh the potential benefits.”

• CagriSema Weight Loss in Women | Novo Nordisk U.S. — Novo Nordisk U.S.

“CagriSema was associated with clinically meaningful weight loss across all menopause stages, with an average weight loss at week 68 of 26.7% in premenopausal women, 24.8% in perimenopausal women and 23.1% in postmenopausal women.”

Daily TopFive for GLP-1 Daily: Ozempic & Wegovy News. Links above go to the original articles. Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com.

FDA inspection reports describe mold, insects and hidden records at two Chinese suppliers of compounded semaglutide and tirzepatide ingredients, now on import alert. Plus a Health Affairs Scholar study on first-fill GLP-1 denials, and the EU drug regulator's committee backing Lilly's Foundayo pill.

In this episode

• FDA Flags Chinese GLP-1 Ingredient Suppliers — Kalbir Talwar

“Inspection reports describe a mess at two Chinese facilities supplying active ingredients for compounded GLP-1 drugs. At Chengdu Shengnuo, inspectors noted black mold on equipment, "gross contamination" on floors, and "significant insect activity" in the ceilings.”

• Prescription Denials For GLP-1 Receptor Agonists Across Commercial, Medicare, And Medicaid Coverage, 2018–2024 | Health Affairs Scholar | Oxford Academic — Jia, Miaoqing, Levy, Joseph F, McGinty, Emma E, Tummalapalli, Sri Lekha, Zhang, Yongkang

“Denial was higher in Medicaid than commercial coverage (12.6% versus 5.6%) and for obesity-indicated than diabetes-indicated brands (16.8% versus 6.3%). Among individuals with a denied index claim, 34.1% obtained a paid fill within 90 days, declining from 45.9% (2018) to 24.8%…”

• EMA CHMP Backs Orforglipron (Foundayo): Non-Peptide GLP-1 EU Approval Implications — BSR — Biotech Research

“The positive opinion covers two separate indications. For weight management, EMA's recommendation is based on two studies involving more than 4,740 adults with obesity or overweight. Participants treated with orforglipron for 72 weeks lost approximately 5 to 11 per cent of their…”

Daily TopFive for GLP-1 Daily: Ozempic & Wegovy News. Links above go to the original articles. Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com.

CBS News obtained two unverified FDA adverse-event reports of deaths after use of products sold as retatrutide, and Walmart will make Ozempic and Mounjaro free in 2027 for employees with type 2 diabetes but still won't cover GLP-1s for weight loss. Plus, a new Annals of Internal Medicine paper finds the Wegovy pill passed 100,000 monthly new prescriptions within two months of launch.

In this episode

• Two deaths were reported to the FDA. Is the bootleg weight-loss drug "Reta" to blame? - CBS News — Daniel Gilbert Investigative Reporter

“The cases appear to be the first public accounts in the U.S. alleging that unauthorized use of retatrutide — or products claiming to contain it — played a role in a patient's death, though the details aren't verified and it is unclear whether the drug was to blame.”

• Walmart employee benefits add no-cost GLP-1s in 2027 — CNBC

“Walmart plans to cover more than 250 prescriptions, including some insulin, inhalers and GLP-1s for diabetes, at no cost to its employees, in 2027, the company confirmed to CNBC.”

• Oral Semaglutide Obesity Rx Tops 100K Monthly in 2 Months — Medscape

“Within 2 months of launch, the oral semaglutide pill surpassed 100,000 monthly new prescriptions. Tirzepatide took 4 months to reach that mark, and injectable semaglutide took 20 months.”

Daily TopFive for GLP-1 Daily: Ozempic & Wegovy News. Links above go to the original articles. Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com.

Eli Lilly is moving against med spas and online sellers marketing its unapproved obesity drug retatrutide, which is still in phase 3. Separately, patent and bioequivalence hurdles suggest a generic Wegovy pill could be more than a decade away.

In this episode

• Lilly is fighting a black market for its new obesity drug even before it launches | PharmaVoice — PharmaVoice

“Eli Lilly is no stranger to competition from compounded versions of its tirzepatide GLP-1 diabetes and weight loss drugs. But the problem recently took a turn into uncharted territory when medical spas, online sellers and other businesses began marketing products purporting to…”

• Wegovy Pill: Sales, Patents, Generic Hurdles – INTO BIOTECH — INTO BIOTECH

“Novo Nordisk’s (NVO) oral obesity drug, the Wegovy pill (oral semaglutide 25 mg), passed DKK 3.2 billion in quarterly sales just two quarters after its U.S. launch. Yet even once its patents start to expire, this pill will be far harder to copy than the injection.”

• GLP-1 Benefits Beyond Weight Loss: 2026 Evidence Scorecard — Inside Peptides

“GLP-1 medicines now have FDA-approved uses well beyond weight loss and blood sugar: lowering heart-attack and stroke risk, slowing kidney disease in type 2 diabetes, treating a serious form of fatty liver disease, and treating obstructive sleep apnea. But not every hopeful…”

Daily TopFive for GLP-1 Daily: Ozempic & Wegovy News. Links above go to the original articles. Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com.

Novo Nordisk's post hoc STEP UP analysis at EASD 2026 says Wegovy brought liver fat below 5 percent in 23 of 26 adults with obesity. We weigh that small, company-presented result and what the oral Wegovy pill does and doesn't change for patients.

In this episode

• Wegovy reduced liver fat to normal levels in 9 out of 10 adults with obesity and excess liver fat at EASD2026 - Novo - Medical Update Online — Medical Update Online

“Novo Nordisk presented post hoc analysis of data from a STEP UP trial sub-population with 55 participants, showing that Wegovy® (pooled semaglutide 7.2 and 2.4 mg) reduced liver fat in adults with obesity without diabetes. Change in percentage of liver fat, determined by…”

• Step Back — Now that the FDA has approved an oral version of Wegovy, what actually changes for patients compared with the weekly injection—and what still depends on insurance coverage, prescribing decisions, and longer-term evidence?

Background sources

• FDA approves Wegovy weight loss pill from Novo Nordisk — Berkeley Lovelace Jr.
• US regulators approve Wegovy pill for weight loss — Associated Press
• Wegovy Weight-Loss Pills Hit U.S. Pharmacies—Costs and Treatments Explained | Scientific American — Lauren J. Young
• What to Know About the New Wegovy Pill | U.S. News — Claire Wolters, Rachael Hood
• Novo's Wegovy pill improves weight loss after switch from injections — Annika Kim Constantino
• Wegovy Pill: What to Know About Oral Wegovy for Weight Loss | Ro — Amelia Willson

Daily TopFive for GLP-1 Daily: Ozempic & Wegovy News. Links above go to the original articles. Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com.

Eli Lilly's once-daily oral GLP-1 orforglipron showed no excess cardiovascular risk against insulin glargine in the 2,749-patient ACHIEVE-4 trial, published in The Lancet. That clears a key regulatory hurdle, while an NEJM perspective warns that obesity drug trials aren't built to detect emerging harms.

In this episode

• Step Back — With the FDA warning Empower Pharmacy over what it calls an “inordinate” number of copies of weight-loss drugs, how does the agency distinguish lawful compounding for individual patients from an impermissible copy—and what should patients ask their prescriber or pharmacy to understand which kind they’re receiving?

Background sources

• Will an FDA crackdown curb access to cheaper GLP-1 weight-loss drugs? Here's what to know. - CBS News — Cbsnews
• FDA Warning Letter to Empower Pharmacy and What It Means for 503A Compounding Pharmacies | Buchanan Ingersoll & Rooney PC — ,
• FDA Warning Letter Targets Compounded GLP-1 Products — Edgar J. Asebey, Guilherme Ferrari Faviero
• FDA Warning Letter To Empower Pharmacy And What It Means For 503A Compounding Pharmacies - Healthcare - United States — Lucas Morgan
• Empower, the B Vitamin, and the Word “Pretextual” — Lumalexlaw
• FDA Warning Letter Questions “Significant Difference” Documentation for Compounded GLP-1s | Spakinect — Paulina Riedler, RN

• Major trial confirms CVD safety of oral GLP‑1RA — The Limbic

“The once-daily oral GLP-1RA orforglipron does not show any excess cardiovascular risks when compared with insulin glargine for patients with type 2 diabetes, data presented at the European Association for the Study of Diabetes 2026 meeting has shown. Highly anticipated results…”

• NEJM Interview: Sarah Schmitz on protections for people enrolled in trials of investigational agents for obesity. — Exa

“So trials of obesity pharmacotherapies have largely been designed with change in BMI as the primary endpoint and a goal of maximizing weight loss. So my concern is that these trials aren't built to detect the harms that have become more likely as obesity pharmacotherapy is…”

Daily TopFive for GLP-1 Daily: Ozempic & Wegovy News. Links above go to the original articles. Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com.

An American Academy of Ophthalmology meeting study links GLP-1 use to faster second-eye NAION, as federal eye-injury cases climb to 247; plus Medicare Bridge paperwork gaps for cash-pay patients, pharmacists seeing more cash GLP-1 fills, the WHO's first childhood obesity guidelines, and Korea's first homegrown GLP-1 obesity drug.

In this episode

• GLP-1 Drugs Linked to Faster Vision Loss in the Second Eye, New Study Finds | Newswise — American Academy of Ophthalmology (AAO

GLP-1 Drugs Linked to Faster Vision Loss in the Second Eye, New Study Finds | Newswise # GLP-1 Drugs Linked to Faster Vision Loss in the Second Eye, New Study Finds ###### Among patients who suffered a rare optic nerve stroke in both eyes, those taking GLP-1 drugs saw the second eye affected sooner. They caution that causation hasn’t been established, only an association. 6-Oct-2026 at 9:30…

• Medicare’s Missing On-Ramp For Access To GLP-1s For Weight Management | Health Affairs — T. Joseph Mattingly II

Medicare’s Missing On-Ramp For Access To GLP-1s For Weight Management | Health Affairs # Medicare’s Missing On-Ramp For Access To GLP-1s For Weight Management - T. Joseph Mattingly II, - Rena M. Conti, - and - Sean D. Sullivan October 7, 2026 Medicare’s GLP-1 Bridge program is off to a fast start, but gaps in prior authorization design may exclude beneficiaries who began GLP-1 therapy…

• Patients increasingly bypass insurance to pay cash for GLP-1 prescriptions, pharmacists say — Bill Schiffner

Patients increasingly bypass insurance to pay cash for GLP-1 prescriptions, pharmacists say # Patients increasingly bypass insurance to pay cash for GLP-1 prescriptions, pharmacists say The trend reflects the rapidly evolving GLP-1 marketplace. , and Bill Schiffner October 7, 2026 . 10:06 AM HIALEAH, Fla. — A growing number of patients are choosing to pay cash for GLP-1 medications…

• Should kids living with obesity be on GLP-1s? New global guidance says yes — in some cases — CBC News

Should kids living with obesity be on GLP-1s? New global guidance says yes — in some cases ## Should kids living with obesity be on GLP-1s? New global guidance says yes — in some cases New Lauren Pelley | CBC News | Posted: October 7, 2026 8:00 AM | Last Updated: Just now World Health Organization has released its first-ever guidelines on managing childhood obesity Image | VANCOUVER NEW…

• MFDS approves Hanmi's EPPE, Korea's first homegrown GLP-1 obesity drug · Local Chorus — Local Chorus

MFDS approves Hanmi's EPPE, Korea's first homegrown GLP-1 obesity drug · Local Chorus # MFDS approves Hanmi's EPPE, Korea's first homegrown GLP-1 obesity drug 🇰🇷 South Korea, Seoul 09:37 Health Business 8 Official updated 2 h ago first reported by 서울경제 Copy link ## In short Korea's Ministry of Food and Drug Safety approved Hanmi Pharmaceutical's EPPE auto-injector (efpeglenatide) on Oct 7,…

Daily TopFive for GLP-1 Daily: Ozempic & Wegovy News. Links above go to the original articles. Follow and rate GLP-1 Daily: Ozempic & Wegovy News on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com.

Medicare's $50-a-month GLP-1 Bridge pilot is denying some obese seniors who have certain diagnoses, such as severe sleep apnea. Separately, Amylyx will present Phase 3 avexitide data for post-bariatric hypoglycemia at ObesityWeek in November.

In this episode

• Amylyx to Present Phase 3 LUCIDITY Data at ObesityWeek | AMLX Stock News — Stock Titan

# Amylyx to Present Phase 3 LUCIDITY Data at ObesityWeek | AMLX Stock News Author: Amylyx Pharmaceuticals, Inc. Published: 2026-10-06T12:00:00Z Source: stocktitan.net Language: en ## Story Amylyx to Present Phase 3 LUCIDITY Data at ObesityWeek | AMLX Stock News # Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at…

• The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don’t Qualify | Sleep Review — Sleep Review

# The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don’t Qualify | Sleep Review Author: Sree Roy Published: 2026-10-06T18:27:06Z Source: sleepreviewmag.com Language: en ## Story The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don’t Qualify | Sleep Review # The Medicare GLP-1 Discount Has One Big Catch: Some Sick Patients Don’t Qualify Oct 6, 2026 | Medicare…

Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com.

Federal employee health plans will require documented intensive behavioral therapy before and during anti-obesity drug treatment in 2027, while the new ADA-EASD consensus backs GLP-1 or SGLT2 drugs early in type 2 diabetes. Plus a phase 3 oral GLP-1 pill, a new SELECT heart analysis, and what's known about GLP-1s in children.

In this episode

• 2027 FEHB Changes: Weight Loss Drug Rules, A New FSA Card, And Plans Leaving | FedSmith.com — Ian Smith

# 2027 FEHB Changes: Weight Loss Drug Rules, A New FSA Card, And Plans Leaving | FedSmith.com Author: Ian Smith Published: 2026-10-05T16:40:00Z Source: fedsmith.com Language: en ## Story 2027 FEHB Changes: Weight Loss Drug Rules, A New FSA Card, And Plans Leaving | FedSmith.com # 2027 FEHB Changes: Weight Loss Drug Rules, a New FSA Card, and Plans Leaving From weight loss drug rules to a new…

• The 2026 Diabetes Consensus Backs GLP-1 or SGLT2 Drugs Early, Possibly From Diagnosis, Without Waiting on Metformin | Peptide News Digest — Peptide News Digest

The 2026 Diabetes Consensus Backs GLP-1 or SGLT2 Drugs Early, Possibly From Diagnosis, Without Waiting on Metformin | Peptide News Digest Evidence Brief October 4, 2026 · 7 min read # The 2026 Diabetes Consensus Backs GLP-1 or SGLT2 Drugs Early, Possibly From Diagnosis, Without Waiting on Metformin The American Diabetes Association and the European Association for the Study of Diabetes…

• Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial | Nature Medicine — Nature Medicine

# Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trial | Nature Medicine Author: Guo, Lixin, Yu, Dongni, Xu, Yimei, Tang, Guo, Peng, Liang Published: 2026-10-05T10:54:20Z Source: nature.com Language: en ## Story Oral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a…

• Semaglutide heart benefits not fully explained by weight loss - The Pharmacist — Victoria Vaughan

Semaglutide heart benefits not fully explained by weight loss - The Pharmacist # Semaglutide heart benefits not fully explained by weight loss By Jerome Smail 5th October 2026 aprott / iStock / Getty Images Plus The cardiovascular benefits of the GLP-1 receptor agonist semaglutide cannot be fully explained by weight loss or improvements in other known risk factors, according to a new…

• Weight loss GLP-1s are everywhere and kids are taking them too. 7 things parents should know – PolitiFact — Madison Czopek

Weight loss GLP-1s are everywhere and kids are taking them too. 7 things parents should know – PolitiFact # Weight loss GLP-1s are everywhere and kids are taking them too. 7 things parents should know Doses of Wegovy, a drug used for weight loss, are stored in a refrigerator at Donna Cooper's home in Front Royal, Va., on March 1, 2024. (AP) By Madison Czopek October 5, 2026 #### If…

Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com.

Rhode Island Medicaid stopped covering GLP-1s prescribed only for weight loss on October 1, and new Massachusetts data shows weight-loss use fell 52% after insurers pulled back. Plus Cigna employees pressing their own employer, a physician's case against the compounding market, and semaglutide's benefits across frailty levels.

In this episode

• Rhode Island Medicaid Ends Coverage of Wegovy,… — Inkl

# Rhode Island Medicaid Ends Coverage of Wegovy, Zepbound, and Other GLP-1 Drugs Prescribed Only for Weight Loss Author: Cole Mercer Published: 2026-10-03T12:50:36Z Source: medicaldaily.com Language: en ## Story Rhode Island Medicaid Ends Coverage of Wegovy, Zepbound, and Other GLP-1 Drugs Prescribed Only for Weight Loss Oct 03, 08:50 am EDT [Medical…

• GLP-1 use for weight loss plunges 52% in Massachusetts after insurers cut coverage — Morgan Taylor

Insurers Cut Coverage — GLP‑1 Weight‑Loss Use in Massachusetts Falls 52%, Impacting 112,000 Patients - CRBC News # Insurers Cut Coverage — GLP‑1 Weight‑Loss Use in Massachusetts Falls 52%, Impacting 112,000 Patients Morgan Taylor| The Cool Down Oct 3• 3 min read 2 Save Massachusetts saw a 52% decline in GLP‑1 use for weight loss between 2025 and Q1 2026 after multiple commercial and state…

• OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage — PR Newswire

OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage # OAC Calls on Cigna to Listen to Employees and Restore GLP-1 Coverage Obesity Action Coalition Oct 02, 2026, 08:15 ET TAMPA, Fla., Oct. 2, 2026 /PRNewswire/ -- The Obesity Action Coalition (OAC) is calling on Cigna to listen to its employees and reconsider its decision to end coverage of GLP-1 medications for weight…

• I'm an obesity expert and can't wait for the compounding craze to stop | Fortune — Adonis Saremi

# I'm an obesity expert and can't wait for the compounding craze to stop | Fortune Author: Adonis Saremi Published: 2026-10-03T11:30:00Z Source: fortune.com Language: en ## Story I'm an obesity expert and can't wait for the compounding craze to stop | Fortune # I’m an obesity expert and can’t wait for the compounding craze to stop By Adonis Saremi October 3, 2026, 7:30 AM ET Dr. Adonis…

• Semaglutide Demonstrates Benefits Across Frailty Levels | Obesity | JAMA | JAMA Network — Samantha Anderer

Semaglutide Demonstrates Benefits Across Frailty Levels | Obesity | JAMA | JAMA Network # Semaglutide Demonstrates Benefits Across Frailty Levels Samantha Anderer Article Information Published Online: October 2, 2026 The glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide demonstrated safety and efficacy regardless of frailty status, a study published in JAMA Cardiology…

Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com.

A JAMA Health Forum study finds GLP-1 nonadherence tops 80% once monthly out-of-pocket costs pass $75, while New Mexico's Medicaid Ozempic spending hit $38.7 million in 2025. Plus survodutide's Phase 3 in NEJM, the amylin tolerability tradeoff, and Novo's injection-to-pill switch data.

In this episode

• Higher GLP-1 costs lead to lower adherence | EurekAlert! — EurekAlert!

Higher GLP-1 costs lead to lower adherence | EurekAlert! News Release 30-Sep-2026 # Higher GLP-1 costs lead to lower adherence Patients significantly less likely to use the weight loss medication when monthly costs exceed $75 University of Georgia Semaglutides, or GLP-1s, can produce substantial weight loss if individuals adhere to their doctor’s instructions. But a new study from the…

• Ozempic driving massive increase in New Mexico Medicaid prescription drug spending | Local News | santafenewmexican.com — Margaret O'Hara mohara@sfnewmexican.com

Ozempic driving massive increase in New Mexico Medicaid prescription drug spending | Local News | santafenewmexican.com # Ozempic driving massive increase in New Mexico Medicaid prescription drug spending Follow Margaret O'Hara - By Margaret O'Hara mohara@sfnewmexican.com #### Margaret O'Hara Health Care Accountability Reporter - Author email (mohara@sfnewmexican.com) - Sep 29, 2026…

• Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes - BioSpace — BioSpace

Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic control in people with obesity and type 2 diabetes - BioSpace # Zealand Pharma announces Boehringer Ingelheim’s survodutide achieves up to 13.1% weight loss in new Phase III trial, alongside significant improvements in glycemic…

• Novel amylin drug confers 10% weight loss, well tolerated — Dorothy Brooks

# Novel amylin drug confers 10% weight loss, well tolerated Author: Erik Swain Published: 2026-09-30T00:00:00 Source: healio.com (healio.com) Language: en ## Story Novel amylin drug confers 10% weight loss, well tolerated By Erik Swain Fact checked by Richard Smith # Novel amylin drug confers 10% weight loss with adverse events comparable to placebo September 30, 2026 5 min read By…

• People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026 — Annika Kim Constantino

# People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on average after three months, according to real-world data presented at EASD2026 Author: NOVO NORDISK INC. Published: 2026-09-30T09:45:00+00:00 Source: prnewswire.com (prnewswire.com) Language: en ## Story People switching from weight-loss injections to Novo's Wegovy® pill lost 4.1% body weight on…

Daily TopFive for GLP-1 Daily. Links above go to the original articles. Follow and rate GLP-1 Daily on Apple Podcasts. Feedback? Email glp-1-daily@lanternpodcasts.com.